【摘要】 急性早幼粒细胞白血病是由急性髓细胞病变引起的一种血液疾病,是分子生物学异常17号染色体上的rARα与15号染色体上的PMI相互易位引起的基因融合现象。患者发病后会表现出凝血异常以及出血障碍,且危险性较高,如果得不到有效的治疗,患者出现死亡的概率非常高。临床治疗过程中,药物治疗是控制该病的有效途径之一,经合理的用药指导能够提升患者治疗效果,为患者病情控制提供帮助。鉴于此,本文以综述视角就急性早幼粒细胞白血病的治疗进展探讨进行了分析,以能够了解该病的发病情况和治疗方案,从而提高患者治疗水平。更多还原

【Abstract】 Acute promyelocytic leukemia(APL) is a blood disease caused by acute myelocytic disease.It is the RAR on chromosome 17,a molecular biological abnormality a Gene fusion caused by translocation with PMI on chromosome 15.Patients will show abnormal coagulation and bleeding disorders after the onset,and the risk of patients after the onset is high,if not effectively treated the probability of death is very high.In the process of clinical treatment,drug treatment is one of the effective ways to control the disease.Reasonable medication guidance can improve the treatment effect of patients and provide help for the disease control of patients.In view of this,this paper analyzes the treatment progress of acute promyelocytic leukemia from the perspective of review,and tries to understand the incidence of the disease with the help of this review,and make a reasonable analysis of the treatment options,so as to improve the treatment level of patients.更多还原